Nmn (Nicotinamide Mononucleotide) for Anti-Aging

Research suggests that NMN has attracted scientific interest primarily as a NAD⁺ precursor with potential relevance to cellular aging processes, though the evidence base for its anti-aging applications in humans remains limited and mixed. The studies reviewed here are largely preclinical — involving mice, fruit flies, cell cultures, and computational models — with no clinical trials represented in this set; one mouse study found that NMN supplementation in aged animals unexpectedly worsened kidney inflammation and injury markers, raising questions about tissue-specific and age-dependent safety, while another computational study using a blood-based gene expression clock reported patterns consistent with a rejuvenating effect on cells in laboratory conditions. Additional studies touched on NMN only tangentially, exploring related NAD⁺ pathway biology in contexts ranging from angiogenesis to viral replication to nerve cell vulnerability, where a related compound (nicotinamide riboside) was shown to have counterproductive effects under certain neurological conditions. Taken together, the available evidence does not yet support broad conclusions about NMN's effectiveness or safety as an anti-aging intervention in humans, and the notably mixed and context-dependent findings across different tissues and age groups highlight the need for well-designed human clinical trials before firmer assessments can be made.